How common is bacterial overgrowth in people with MCAS?

Figures circulate in the range of thirty percent, and they come from specialist clinic populations. Everyone in those samples was referred for being difficult to explain, which inflates any co-occurrence rate relative to the general population. Treat the number as describing that clinic, not you.

What is referral bias in plain terms?

If a clinic only sees people who have already failed elsewhere, then everything it counts will look more common and more clustered than it is. Two conditions can appear strongly linked in that setting purely because having both is what got you referred.

Can one trigger the other?

Both directions have been proposed and neither is established. Mediator release affecting gut motility is plausible; altered gut populations affecting mast cell activity is also plausible. Plausible is not demonstrated, and no study currently settles the ordering.

Which is easier to confirm?

Bacterial overgrowth, and only relatively. It has a breath test with published thresholds, though specialists actively dispute whether that test should be used. Mast cell criteria require mediator measurements with strict sample handling and two competing criteria sets disagree on who qualifies.

What should I ask a clinician?

Which specific tests they are proposing, what each can physically measure, and what a negative would and would not rule out. Those are answerable questions, unlike asking which of two contested labels applies to you.

Is it SIBO or MCAS?

By B. Gray Randolph · Updated August 4, 2026

This pair comes with a statistical trap attached, and almost nothing written for patients mentions it.

What actually separates them

Bacterial overgrowth is a test result about gas production in the small intestine. Mast cell activation syndrome is a criteria-based description of immune cells releasing mediators throughout the body. One is local and measurable, if imperfectly. The other is systemic and defined by criteria that specialists dispute.

How often patients discuss both

6,296comments mention both overgrowth and mast cell activation

out of 7,205,554 comments across 18 patient subreddits, 2011-02-24 to 2026-05-26

query: ("sibo" OR "small intestinal bacterial overgrowth") AND ("mcas" OR "mast cell activation")

How this was measured, and its limits · reddit.db@a313e531

About 2.8% of overgrowth comments and 3.1% of mast cell comments. Notably lower than the mast cell overlap with histamine intolerance, long COVID or dysautonomia, which is worth holding in mind when you read a clinic page describing this pair as tightly linked.

The referral bias problem

Prevalence figures connecting these two come from specialist clinic populations. Everyone in such a sample was referred for being difficult to explain. Two conditions will look strongly linked in that setting partly because having both is what got a person referred in the first place. The number describes the clinic, not the general population, and not you.

This is not a criticism of the clinicians who published those figures. A specialist clinic is where these patients are, so it is where the data comes from. The error is in reading a clinic co-occurrence rate as though it were a population rate, which is what happens every time one of those percentages gets quoted on a supplement page.

What the guideline says about symptoms

Pimentel M et al., American Journal of Gastroenterology 2020 Clinical guideline

No single symptom can be specifically attributed to overgrowth, and five of six recommendations rest on evidence graded very low quality by the authors themselves. If that is the state of the condition with a test, symptom-matching your way to a conclusion about a pair of overlapping conditions is not going to work.

What to do next

Ask which tests are proposed, what each can physically measure, and what a negative would rule out. Those questions have answers. The question of which of two contested labels applies to you frequently does not.

Common questions

How common is bacterial overgrowth in people with MCAS?: Figures circulate in the range of thirty percent, and they come from specialist clinic populations. Everyone in those samples was referred for being difficult to explain, which inflates any co-occurrence rate relative to the general population. Treat the number as describing that clinic, not you.
What is referral bias in plain terms?: If a clinic only sees people who have already failed elsewhere, then everything it counts will look more common and more clustered than it is. Two conditions can appear strongly linked in that setting purely because having both is what got you referred.
Can one trigger the other?: Both directions have been proposed and neither is established. Mediator release affecting gut motility is plausible; altered gut populations affecting mast cell activity is also plausible. Plausible is not demonstrated, and no study currently settles the ordering.
Which is easier to confirm?: Bacterial overgrowth, and only relatively. It has a breath test with published thresholds, though specialists actively dispute whether that test should be used. Mast cell criteria require mediator measurements with strict sample handling and two competing criteria sets disagree on who qualifies.
What should I ask a clinician?: Which specific tests they are proposing, what each can physically measure, and what a negative would and would not rule out. Those are answerable questions, unlike asking which of two contested labels applies to you.